Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Contract Type
partnership
Ingelheim am RheinPharmaceuticalpharmaceuticalsDescription
Boehringer Ingelheim has expanded its cancer pipeline through two licensing agreements with Lonza's Synaffix and Oxford BioTherapeutics. The partnership with Synaffix involves an undisclosed upfront payment and up to $1.3 billion in milestones, along with royalties on potential product sales. This deal provides Boehringer access to Synaffix's proprietary ADC platform for developing therapies for multiple cancer targets.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months